论文部分内容阅读
目的:探讨替吉奥胶囊在晚期胃癌姑息化疗中的疗效和安全性。方法:回顾性分析我院2012年8月至2015年7月收治的116例晚期胃癌患者,根据治疗方案分为两组,治疗组64例给予替吉奥胶囊口服化疗,对照组52例给予奥沙利铂联合氟尿嘧啶(5-FU)治疗,两组治疗期间均给予止吐、保肝等常规治疗,所有患者均随访9~12月,对比两组化疗疗效、不良反应发生率、疾病控制率和无进展生存时间。结果:治疗组疾病控制率为76.56%,对照组为67.31%,组间差异具有统计学意义(p<0.05);治疗组无进展生存时间为(6.15±2.37)月,对照组为(4.08±1.42)月,组间差异具有统计学意义(p<0.05);治疗组胃肠道毒性、肝脏毒性、肾脏毒性和对照组比较差异具有统计学意义(p<0.05)。结论:替吉奥胶囊在晚期胃癌姑息化疗中疗效良好,不良反应能够耐受,在延长患者无进展生存时间方面效果显著。
Objective: To investigate the efficacy and safety of TIGO capsule in palliative chemotherapy of advanced gastric cancer. Methods: A retrospective analysis of 116 patients with advanced gastric cancer admitted from August 2012 to July 2015 in our hospital was divided into two groups according to the treatment regimen. 64 patients in the treatment group were treated with TIGO capsules orally, while 52 patients in the control group were given All the patients were followed up for 9 ~ 12 months. The curative effect, adverse reaction rate and disease control rate were compared between the two groups And progression-free survival time. Results: The disease control rate was 76.56% in the treatment group and 67.31% in the control group, the difference was statistically significant (p <0.05); the progression-free survival time was 6.15 ± 2.37 months in the treatment group and 4.08 ± 1.42) months, the difference between the groups was statistically significant (p <0.05). The gastrointestinal tract toxicity, liver toxicity and nephrotoxicity in the treatment group were significantly different from those in the control group (p <0.05). Conclusion: Tigiao capsule is effective in palliative chemotherapy of advanced gastric cancer and its adverse reaction can be tolerated. It has a significant effect in prolonging the progression-free survival time of patients.